N/A
Completed N=227
Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension
Source: ClinicalTrials.gov NCT01365585 ↗Enrolled (actual)
227
Serious AEs
0.0%
Results posted
Oct 2012
Primary outcomePrimary: Change From Baseline in 6-Minute Walk Distance (6MWD) at Year 1 — 29.4 meter
Summary
The objective of this observational study is to gain clinical insight on the actual use of sildenafil citrate (Revatio™) for the treatment of pulmonary arterial hypertension (PAH). The primary objective is to assess effectiveness and safety of sildenafil at doses ≥20mg three times daily for the treatment of PAH.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in 6-Minute Walk Distance (6MWD) at Year 1 |
29.4 | — |
| PRIMARY Change From Baseline in 6-Minute Walk Distance (6MWD) at Year 2 |
20.8 | — |
| PRIMARY Change From Baseline in 6-Minute Walk Distance (6MWD) at Year 3 |
8.7 | — |
| PRIMARY Change From Baseline in 6-Minute Walk Distance (6MWD) at Year 4 |
-50.2 | — |
| SECONDARY Change From Baseline in New York Heart Association, World Health Organization (NYHA/WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Year 1, 2, 3 and 4 |
3; 36; 140; 12; 5; 1 | — |
| SECONDARY Change From Baseline in Right Atrial Pressure (RAP) at Year 1, 2, 3 and 4 |
— | — |
| SECONDARY Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) at Rest at Year 1, 2, 3 and 4 |
— | — |
| SECONDARY Change From Baseline in Pulmonary Vascular Resistance (PVR) at Year 1, 2, 3 and 4 |
— | — |
| SECONDARY Change From Baseline in Cardiac Index (CI) at Year 1, 2, 3 and 4 |
— | — |
| SECONDARY Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Year 1, 2, 3 and 4 |
— | — |
| SECONDARY Change From Baseline in Borg Dyspnea Index at Year 1, 2, 3 and 4 |
-0.4; 0.0; 0.3; 0.4 | — |
Eligibility Criteria
Inclusion Criteria
- Patients must be at least 18 years of age at study index;
- Patients must have a diagnosis of PAH. PAH is conventionally defined as a mean pulmonary arterial pressure (PAP) of > 25 mmHg and a pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg and a pulmonary vascular resistance (PVR) ≥ 240 dynes/s/cm-5 at right heart catheterization;
- Patients must have initiated sildenafil for the treatment of their PAH; at dose ≥ 20 mg tid within 5 years prior to study initiation
Exclusion Criteria
- Patient has known contraindications to sildenafil at study index;
- Patient participated in an investigational study of sildenafil treatment for PAH during the period beginning 6 months prior to study index
Data sourced from ClinicalTrials.gov (NCT01365585). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.